Literature DB >> 28582423

Correction: The impact of anti-drug antibodies on drug concentrations and clinical outcomes in rheumatoid arthritis patients treated with adalimumab, etanercept, or infliximab: Results from a multinational, real-world clinical practice, non-interventional study.

Robert J Moots, Ricardo M Xavier, Chi Chiu Mok, Mahboob U Rahman, Wen-Chan Tsai, Mustafa H Al-Maini, Karel Pavelka, Ehab Mahgoub, Sameer Kotak, Joan Korth-Bradley, Ron Pedersen, Linda Mele, Qi Shen, Bonnie Vlahos.   

Abstract

[This corrects the article DOI: 10.1371/journal.pone.0175207.].

Entities:  

Year:  2017        PMID： 28582423      PMCID： PMC5459555          DOI： 10.1371/journal.pone.0179308

Source DB:  PubMed          Journal:  PLoS One        ISSN： 1932-6203            Impact factor:   3.240


The images for Figs 4, 5, and 6 are incorrectly switched. The image that appears as Fig 4 should be Fig 5, the image that appears as Fig 5 should be Fig 6, and the image that appears as Fig 6 should be Fig 4. The figure captions appear in the correct order.
  1 in total

1.  The impact of anti-drug antibodies on drug concentrations and clinical outcomes in rheumatoid arthritis patients treated with adalimumab, etanercept, or infliximab: Results from a multinational, real-world clinical practice, non-interventional study.

Authors:  Robert J Moots; Ricardo M Xavier; Chi Chiu Mok; Mahboob U Rahman; Wen-Chan Tsai; Mustafa H Al-Maini; Karel Pavelka; Ehab Mahgoub; Sameer Kotak; Joan Korth-Bradley; Ron Pedersen; Linda Mele; Qi Shen; Bonnie Vlahos
Journal:  PLoS One       Date:  2017-04-27       Impact factor: 3.240
  1 in total
  1 in total

1.  Anti-infliximab antibodies and clinical response in noninfectious uveitis and scleritis patients treated with infliximab: A retrospective review.

Authors:  Lianna Valdes; Jacob T Cox; Janine Yang; Gayatri Susarla; Samuel Han; George N Papaliodis; Lucia Sobrin
Journal:  Am J Ophthalmol Case Rep       Date:  2022-06-25
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.